Adhoc: Kinarus Therapeutics Holding AG: Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Kinarus Therapeutics Holding AG / Key word(s): Research Update/Study Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients 29-Aug-2022 / 07:00 CET/CEST Release
Chris Maggos Thierry Fumeaux Kinarus Therapeutics Holding Ag Key Swiss Federal Office Of Public Health Research Update Study Swiss Federal Council
Source: finanznachrichten.de